References
- Low Louis C. K. Growth of children with β‐thalassemia major. Indian J Pediatr 2005; 72: 159–64
- Bazrafshan H. R., Mohammadian S., Azizi F., Mehrabi Y. Delayed puberty in patients with thalassemia major. J Mazandaran Uni Med Sci 1999; 24: 39–43
- Abdulrazzaq Y. M., Ibrahim A., Al‐Khayat A. I., Dawson K. β‐Thalassemia major and its effect on amino acid metabolism and growth in patients in the United Arab Emirates. Clin Chim Acta 2005; 352((1–2))183–90
- Shalitin S., Carmi D., Weintrob N., Phillip M., Miskin H., Kornreich L., et al. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol 2005; 74: 93–100
- Soliman A. T., Nasr I., Thabet A., Rizk M. M., Matary W. E. Human chorionic gonadotropin therapy in adolescent boys with constitutional delayed puberty vs those with β‐thalassemia major. Metab Clin Exp 2005; 54: 15–23
- Jordan W. P., Atkinson L. E., Lai C. Comparison of the skin irritation potential of two testosterone transdermal systems: An investigational system and a marketed product. Clin Ther 1998; 20: 80–7
- Khodai S., Karbakhsh M., Asasi N. Psychosocial status in Iranian adolescents with beta‐thalassemia major. J Fac Med (Tehran Uni Med Sci) 2005; 63: 18–23
- Slater C. C., Souter I., Zhang C., Guan C., Stanczyk F. Z., Mishell D. R. Pharmacokinetic of testosterone after percutaneous gel or buccal administration. Fertil Steril 2001; 76: 32–7
- Galasso F., Altamura V., Sbano E. Effects of topical testosterone propionate on the positive nickel patch test. J Dermatol Sci 1996; 13: 76–82
- Saeedi M., Morteza‐Semnani K., Ghoreishi M. R. The treatment of atopic dermatitis with licorice gel. J Dermatol Treat 2003; 14: 153–7
- Kattamis A. C., Antoniadis M., Manoli I., Kitra V., Petropoulos D., Grafacos S. Endocrine problem in ex‐thalassemic patients. Transfus Sci 2000; 23: 251–2
- Anoussakis C., Alexiou D., Abatzis D., Bechrakis G. Endocrinological investigation of pituitary conadal axis in thalassemia major. Acta Pediatr Scand 1977; 66: 49–51
- Marin P., Holmang S., Jonsson L., Sjostrom L., Kvist H., Holm G., et al. The effect of testosterone treatment on body composition and metabolism in middle‐aged obese men. Int J Obes 1992; 16: 991–7
- Valenti S., Giusti M., McGuinness D., Guido R., Mori P. G., Giordano G., et al. Delayed puberty in males with beta‐thalassemia major: Pulsatile gonadotropin‐releasing hormone administration induces changes in gonadotropin isoform profiles and an increase in sex steroids. Eur J Endocrinol 1995; 133: 48–56
- Kim M. K., Zhao H., Lee C. H., Kim D. D. Formulation of a reservoir‐type testosterone transdermal delivery system. Int J Pharm 2001; 219((1–2))51–9
- De Sanctis V., Vullo C., Urso L., Rigolin F., Cavallini A., Caramelli K., et al. Clinical experience using the andoderm testosterone transdermal system in hypogonadal adolescents and young men with beta‐thalassemia major. J Pediatr Endocrinol Metab 1998; 11: 891–900
- Moore N., Paux G., Noblet C., Andrejak M. Spouce related drug side effects. Lancet 1988; 27: 468
- Delanoe D., Fougeyrollas B., Meyer L., Thonneau P. Androgenization of female partners of men on medroxyprogesterone acetate/percutaneous testosterone contraception. Lancet 1984; 24: 276
- Bennett N. J. A burn‐like lesion caused by a testosterone transdermal system. Burns 1998; 24: 478–80
- Wilson D. E., Kaidbey K., Boike S. C., Jorkasky D. K. Use of topical corticosteroid pretreatment to reduce the incidence and severity of skin reactions associated with testosterone transdermal therapy. Clin Ther 1998; 20: 299–306